| Detailed information |
|---|
| CancerLivER ID | 2323 |
| Biomarker | LOC388796, A_32_P406142, SAFB, MKL1, TNKS1BP1, PMM2, PPP2R5C, SAFB2, GATA4, RASD1, KIAA1967, |
| Biomarker Name/Symbol (given in Publication) | 11 genes-signature (LOC388796, A_32_P406142, SAFB, MKL1, TNKS1BP1, PMM2, PPP2R5C, SAFB2, GATA4, RASD1, KIAA1967) |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Strong predictor for RFS in late-recurring (>1 year) and validated on independent dataset |
| Experimental Condition | early occurrence v/s late recurrence |
| Cancer type | Hepatocellular carcinoma |
| Regulation | over expressed in subjects with fastest recurrence |
| Level of significance | p < 0.0001 |
| Source | Tissue |
| PMID | 20380719 |
| Type of Biomarker | Prognostic |
| Pathway | NA |
| Cohort | 90 HCV-associated HCC patients; 44 Nontumoral HCC; 8 metastatic liver tumors |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCV associated HCC |
| Year of Publication | 2010 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |